19 funding opportunities found in this category. Change the order of results: Newest First Oldest First Expiring Soonest Expiring Latest Lowest Award to Highest Highest Award to Lowest
Young Investigator Award Presidential Grants from the NMS-Group
Symposium Summary: Sleep research in neurodegeneration has become a rapidly growing field of research with major clinical and scientific impact. REM sleep behavior disorder (RBD) as a hallmark and risk factor of neurodegeneration has gained prominent recognition in the last 15 years, identifying those patients at increased risk for neurodegenerative diseases. Idiopathic RBD patients will most likely comprise the ideal population for enrollment in neuroprotective trials in the future. We learn from sleep disorders about the pathophysiology of brain functioning in Parkinson syndromes and we can better define various phenotypes of Parkinson disease. Animal studies will be another focus in this research area, to study the interaction of Gaba-ergic, cholinergic and dopaminergic neurotransmission in the generation of REM sleep, REM without atonia and RBD.
Application Process: We invite all young researchers who are active in the field of clinical or experimental sleep research in a topic related to neurodegeneration (i.e. Parkinson syndromes or Alzheimer disease) or neurobiology of REM sleep to submit their abstracts and apply for a travel grant – with the chance of being selected to present their work in a special symposium entitled “Neurodegeneration and Sleep” at the 5th World Congress on Sleep Medicine in Valencia, Spain.
STEP ONE – Submit your abstract online at www.wasmcongress.com/abstract/submit_form.php. -Select the box “Young Investigator”
STEP TWO – Email WASM at info@wasmonline.org. Within your email add why you are applying for this award with a short letter (max 200 words) and biosketch.
Deadline: June 30, 2013
Requirement: 35 years old or younger OR less than 3 years in that topic.
If selected your 10 minute oral presentation will be included in a special symposium during the meeting on Tuesday, October 1st from noon to 1:30 PM.
A travel grant of $1000-1500 (depending on distance of travel) will be provided to symposium speakers.
Request for Proposals: Parkin Biology and Therapeutic Development Studies
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) seeks to fund pre-clinical studies that investigate the biological function and therapeutic potential of Parkin protein. The ultimate goal is to identify therapeutic agents that alter the course of Parkinson’s disease.
There will be two separate ‘Tracks’ that may be pursued for support around Parkin as follows:
TRACK A – Biology
TRACK B – Therapeutic Development
Applicants may submit proposals to both Track A and Track B but it will need to do so by submitting separate applications that provide independent experimental designs for each. Applicants will be asked to justify the approach and to provide details of their study design.
Biological Studies
How will the proposed studies impact our understanding of Parkin:
As an enzyme
In cell biology
Therapeutic Development Studies
Current drug development stage with clear justification
Provide research operation plan, including feasibility, timelines, and all assays to be performed
Provide a clear description of the properties of the lead compound(s)/biologic
Please ensure that you utilize the correct template upon submission.
DEADLINES
Informational Conference Call*: June 6, 2013, 12:00 p.m. EST
Pre-proposals Due: June 19, 2013, 6:00 p.m. EST
Full Application Invites Sent to Applicants: July 3, 2013
Full Applications Due (by invite only): August 14, 2013
Anticipated Award Announcement: October, 2013
Anticipated Funding: November, 2013
*MJFF will hold a 45-minute conference call at the time listed above to clarify and explain the goals of this funding initiative and answer applicant questions. To participate in the call and receive call-in details, please RSVP via email to conferencecalls@michaeljfox.org, reporting “Parkin 2013” in the subject of the email.
BACKGROUND AND RATIONALE
PD is a progressive neurodegenerative disease affecting nearly five million people worldwide, with significant prevalence growth expected due to an aging population. Current therapies are effective in addressing only the mild-to-moderate motor symptoms of the disease and have significant long-term side effects. There are few specific drugs available that target the numerous non-motor aspects of the disease or the underlying degenerative process.
Though most cases of PD are considered idiopathic, investigators are increasingly identifying genes linked to this disease. However, these monogenic variants account for only a small proportion of all PD cases. Research on genetically implicated targets and associated pathways has the potential to yield critical insight and the development of therapeutics that may impact sporadic PD patients as well.
Parkin (PARK2) was identified as a gene linked to autosomal recessive juvenile forms of PD. Since its original discovery, many mutations and deletions have been identified (1). Parkin gene encodes a multidomain protein that contains E3 ubiquitin ligase activity that plays a role in the regulation of numerous cellular activities including proteasomal degradation of substrates but also ubiquitin-mediated signaling (1). Parkin has also been suggested to function as a transcription factor, regulating p53 expression (2) independent of its ligase activity.
Thus there is the distinct possibility that promoting Parkin activation may have implications in ameliorating cellular signaling pathways as well as regulation of degradation pathways. Given recent advances in understanding Parkin structure, investigators now have at hand a tangible means of optimizing small-molecule development through structure-based drug design.
PURPOSE
The goal of the Parkin Biology & Therapeutic Development Program is to support:
1. Studies that provide critical insight into the biological mechanisms of Parkin function
2. Discovery and development of therapeutic agents that have the potential to modulate Parkin function in a manner that will alter the course of Parkinson’s disease progression.
Although most traditional therapeutics targeting modulation of enzymatic activity involve small-molecule development, MJFF is also open to alternative strategies, including gene therapy and biological (non-pharmaceutical) approaches that can have significant impact on Parkin activity. Moreover, as drug targets may be shared among multiple diseases and/or drugs may hit multiple disease targets, MJFF is also interested in drug repositioning of molecules for Parkin that have been approved or shown to be clinically safe for other indications.
Proposals may seek support of key steps along the entire therapeutic pipeline, including:
High-throughput screening
Primary assay development and validation
IC50 generation/validation in second primary assay and chemistry support for hit ranking and clustering
Hit-to Lead and Lead Optimization
Chemistry support
In vitro and in vivo PK, PK/PD relationships, toxicity studies
Applicants are asked to develop a clear plan, including major ‘go/no go’ decision milestones, for moving a therapeutic strategy toward ultimate clinical utility in people with PD. Investigators new to PD research are encouraged to collaborate with experienced PD scientists and/or companies to ensure the greatest chance for success.
REFERENCES
1.Cell Mol Life Sci (2012) 69:3053-3067
2.Neurodegenerative Dis 2012 10:49-51
FUNDS AVAILABLE
MJFF will commit up to $2 million to the Parkin Biology & Therapeutic Development Program with the intention to support multiple awards. The requested support should be commensurate with the stage of development and work proposed.
Investigators applying to Track A (Biology) may request up to $125,000 in support (inclusive of indirect costs) for up to one year.
For those applying to Track B (Therapeutic Development) there is no set budget limit for proposals and applicants may request up to two years of funding for preclinical development.
No more than 25% (Academic institutions) or 10% (for-profit institutions) of direct costs may go to indirect costs. Please see the program instructions, Administrative Guidelines and our FAQ on MJFF indirect cost policy for details. MJFF reserves the right to reduce the duration and budget based on its review and final funding decision.
Eligibility Requirements
Applications may be submitted by:
U.S. and non-U.S. biotechnology/pharmaceutical companies or other for-profit entities, either publicly or privately held,
U.S. and non-U.S. entities, public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
As therapeutic programs may require many kinds of expertise, MJFF encourages industry and academic collaborations when appropriate. Given the significant coordination and leadership necessary for this program, post-doctoral fellows are NOT eligible to apply as PIs.
Request for Proposals: Funding Opportunities for Kennedy’s Disease Research
The Kennedy’s Disease Association (KDA) is planning to fund one or more research grants this fall to further the understanding of the pathological mechanisms of Kennedy’s Disease.
The KDA projects that funding for each grant will be up to $25,000.
Applications from junior investigators and from senior post-doctoral fellows are encouraged.
Your proposals must be received by Friday, June 21, 2013.
ALS Therapy Alliance Grants Program
Thank you for your interest in submitting a proposal for grant funding to the ALS Therapy Alliance (ATA). Our organization traditionally awards grants from one to three years in term ranging from $100,000 to $1 million in funding to both non- and for-profit companies. National and international companies are eligible to apply.
The following outline will help you prepare the information needed for our next funding review, which happens twice a year in April and November.
Please note grant submission deadlines and number of copies requested in order to ensure timely processing of your application. The ALS Therapy Alliance does not cover indirect costs.
If you have questions about the submission process or this application, please contact Ray Bisson, Grants Manager at (603) 664-5005 or ray@alstherapyalliance.org, or visit our FAQ page.
http://alstherapyalliance.org/index.php/research/grant-submission-process/faqs.html
What to include with your grant proposal
ATA grant applications should follow the following format and adhere strictly to the maximum page limits (using only 11 point font or greater):
■ Abstract (1 page)
■ Background and Significance (2 pages)
■ Preliminary Data (2 pages)
■ Experimental Plan (3 pages)
■ References (no limit)
■ Budget
■ Budget Justification
■ NIH Biosketch (including present and pending support, 4 pages maximum) for PI's, post-docs and others involved in the project (excluding laboratory technicians)
■ Letters of collaboration and support
Grant proposal submission deadlines
To have your grant proposal reviewed at our April meeting, please submit by March 15th. To have your grant proposal reviewed at our November meeting, please submit by October 15th.
Where to send your grant proposal
Please email your proposal in PDF format to ray@alstherapyalliance.org.
Call for Proposals: NCL Research Award for Research on Batten Disease
The NCL Foundation provides regulary the NCL research award. The goal is to find a cure against the deadly children's disease Neuronal Ceroid Lipofuscinosis (NCL), also called Batten disease. This metabolic disorder is the most common neurodegenerative disease of childhood and is inevitably fatal. The gradual stages of the suffering are blindness, dementia, epilepsy, loss of speech, paralysis and complete helplessness.
We invite medical and basic science researchers worldwide to submit innovative clinical oriented or translational basic science projects, which can contribute to finding a cure for juvenile NCL.
Scientists from related areas of science including Alzheimer's disease, aging, and other lysosomal storage disorders, are particularly encouraged to apply with the aim to extend the NCL research community in move more efficiently towards a cure for NCL.
NCL Research Award 2013
This year, the NCL Foundation offers for the fifth time the NCL Research Award.
Grant monies (100,000 euros) are to be used for a postdoctoral fellowship in order to undertake the research project. In this fashion our goal is to promote the next generation of young NCL research scientists.
The deadline for applications: October 31, 2013
Please send the required documents to: Research@ncl-foundation.com
Clinician-Scientist Development Three-Year Award in Parkinson's Disease
Co-sponsored by the American Brain Foundation and the Parkinson's Disease Foundation
Application Deadline: October 1, 2013
The American Brain Foundation, the foundation of the American Academy of Neurology, and the Parkinson’s Disease Foundation are pleased to announce a three-year Clinician-Scientist Development Award to support a clinician scientist’s research related to Parkinson’s Disease.
The three-year award will consist of an annual salary of $75,000 plus $5,000 in educational expenses, per year. Supplementation of the stipend with other grants or by the fellowship institution is permissible, but fellows may not accept other fellowships, similar awards, or have another source of support for more than 50 percent of their research salary during the first year of an American Brain Foundation Clinical Research Training Fellowship. If similar awards are obtained after completion of the first year of the American Brain Foundation Clinical Research Training Fellowship, fellows are required to submit a revised budget for review by executive members of the American Brain Foundation Research Committee or may need to forfeit the rest of the American Brain Foundation award. Only direct costs will be funded by this award.
ELIGIBILITY
1. Must be a neurologist interested in an academic career in clinical research.* Applicants must hold an MD, DO, or equivalent clinical degree from an accredited institution, and must be licensed to practice medicine in the United States.
2. Applicants must have completed residency training but be less than seven years from completion of residency when funding begins.
3. There is no citizenship requirement; however, the individual applying for the award must be licensed to practice medicine in the United States at the time of application.
Clinical research is defined as ”patient-oriented research conducted with human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurological disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research.” Disease-related studies not directly involving humans or human tissue also are encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological disease.
For More Information
Kristin Roehl
Grants Program Manager kroehl@aan.com (612) 928-6082
Clinician-Scientist Development Award in Multiple Sclerosis
Co-sponsored by the American Brain Foundation and the National MS Society
Application Deadline: August 15, 2013
Funding Start Date: July 1, 2014
The American Brain Foundation, the foundation of the American Academy of Neurology, and the National MS Society are pleased to announce a 3-year award to support the training of young physicians committed to a career in academic medicine in an environment where problems in multiple sclerosis are addressed with the most current scientific tools. The salary is approximately $75,000/year (stipend from National MS Society based on postgraduate level plus $25,000 from the American Brain Foundation). We invite our outstanding senior residents to develop a clinically-relevant project at a US institution with a mentor who has experience in MS research.
There is no citizenship requirement, but applicants must hold an MD, DO, or equivalent degree, be at the PGY4 or PGY5 stage of an accredited residency program in the US, and hold a US medical license. Potential applicants must contact the National MS Society to confirm eligibility.
APPLICATION PROCESS
To submit a proposal for research support, investigators must first register with our apply online site, www.mssocietyapplyonline.org, and complete a pre-application, which will be reviewed to determine whether the research plan is appropriate and relevant to the award goals.
EVALUATION PROCESS
Applications are reviewed by the National MS Society Fellowship Advisory Committee and the American Brain Foundation Research Council and must be approved by both. A telephone interview is required. Evaluation criteria include the potential for the trainee to develop into a productive physician scientist, the strength of the training environment and training plan, and the quality of the research proposal.
Additional details about this training award can be found at: www.nationalmssociety.org/researchfunding
If you are interested in applying for the National MS Society – American Brain Foundation MS Clinician-Scientist Development Award or have any questions about the program, please contact:
Jennifer Stark, PhD Director of Research Training Programs National Multiple Sclerosis Society Phone: (212) 476-0462 Email: jennifer.stark@nmss.org
Request for Proposals: Association for Frontotemporal Degeneration Pilot Grant
Maximum Award: $60,000 for one year
AFTD provides support for basic and clinical research in frontotemporal degeneration and related clinical conditions (frontotemporal dementia, primary progressive asphasia, progressive supranuclear palsy and corticobasal syndrome). This grant is designed to seed original projects, with the goal of generating preliminary data toward a larger grant application to the NIH or other public or private agencies concerned with this important medical and social problem.
Applications due: July 1, 2013
Award date: October 1, 2013
Grant period: November 1, 2013 – November 1, 2014
National Ataxia Foundation Pioneer Spinocerebellar Ataxias Translational Research Award
The National Ataxia Foundation (NAF) is committed to funding the best science relevant to hereditary and sporadic types of ataxia in both basic and translational research. Funding for Ataxia-Telangiectasia research proposals will receive a lower priority unless they lend themselves to an overall better understanding of the ataxia disease process.
Pioneer SCA Translational Research Award: Three (3) one-year grants of $100,000 focusing on research investigations that will facilitate the development of treatments for the Spinocerebellar Ataxias (SCAs) will be awarded.
A Letter of Intent is REQUIRED prior to submitting a Pioneer Grant application. Pioneer Grant Applications submitted that were not preceded by a Letter of Intent, will NOT be reviewed.
August 15, 2013 - Letter of Intent with a ½ to one-page abstract with specific aims of your research.
September 15, 2013 - Full application due
Need More Information?
National Ataxia Foundation 2600 Fernbrook Lane Suite 119 Minneapolis, MN 55447-4752
Phone: (763)553-0020 Fax: (763) 553-0167 E-Mail: naf@ataxia.org
12next
